

**Open Access** 

## M Prasad1\*, Ananya Chakraborty1 and Shashidhar VK2

<sup>1</sup>Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, White Field, Bangalore, Karnataka, India <sup>2</sup>Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Centre, White Field, Bangalore, Karnataka, India

## Abstract

Aim:

Materials and methods:

Conclusion:

Copyright:

e eda fgcccdeeead ca ed ce e c ce f e a v c f e e da e a Devae a e.Pe de aede a ed e e cac, afe, a d c e e c e e f OLN e APR eg e CINV. Bee ed ab e eed f f e de a ge a e ze add e e cac, afe, a d e ab f e eg e [9]. O e a e e a c e e a ed e bedacef Ida a gOLN a d APR eg e HEC [10]. с

W bacg d, e ee d de ae de ae ee cac ad afe fOLN ad APR eg e e ea e fHEC d ced CINV.

the second provide the second provide the second provides the seco

a a a dzed, ece, e abe, a dca e dcdced ed cacg de a e a V de I e f Med ca Sce ce a d Reea cCee. e da fe da e ea fJa a 2017 Dece be 2017.

Sa e ze a cac a ed be 32 eac g . e d c ded a c a f e e ge de aged be ee 18 60 , ece g c e e a HEC (C a , C c a de, Ca e, D v b c , If fa de, E b c , Dacabaz e) a d e e g de a e f ed c e .

e devo ded ceaeae, eaegc d ed ca, ad ea.ae ba ga e a eaa,ae e a,GIb c,ae e g cad de e.g.Pa deae, cd , ae ced dabee.Peg a ad acag e eea cded d.

Paca ec ceaadceed ed eead zedbaed cegeeaedabe ef g 2g :

- Tab O a za e 10 g / a
- I Pa e 0.25 g..a
- I Devae a e20 g..a
- . . . . .
- Tab O a za e 10 g / ce da
- , .  **(** . . . , , . ,
- TabAea 125 g / a
- I.Pa e 0.25 g.a
- I.Devaea e12 g.a
- . . . . .
- Tab A e a 80 g / ce da
- Tab De 🛪 e a e 8 g / ce da
- . .
- Tab De 🛪 e a e 8 g / ce da

Pae eef ed a 24,72 ad 6 da ce ea.eegeada ed e bef e de faeaad g,a adeeeac,adece ed ca ed fedafce ea da 6 ea. E cacaeedbaed ceeeeeae( g, ece)a 24 (aceed),72 ad 6 da ceea (deaeded).

Receed ca fI.O dae 4 g..ge a ae dd e d ab eeg e.Qa f fe a a eed baed FLIE cae [11].I a a daed ef-e e ae c g f 18 e , 9 a ea ec c a d 9 g ec c e .Eac e a e ecaeg e c a ge f e ee a d ed ea a ba4 2 ()3 (a-0.052 T9 (d) 4 -6 (a) -5eBVT 0 -1.2)-7 (a)3 ()13 ()8 18 eC Ae **a** f 16 (d)

Page 2 of 5



SEX	Group A (OPD)	Group B (APD)

Table 2

Tabe 3 a d F g e 3.

D b faca baed ccef ce ea Tabe4.

e a e d Tabe 5 a d F g e 4.

feceedca g a Tabe6.

Tabe 7 a d Fg e 5.

Diagnosis	Group A (OPD)	Group B (APD)

Table 3:





## Citation:

Page 4 of 5

Citation:

Page 5 of 5